Padilla Angel M, Bustamante Juan M, Tarleton Rick L
Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA 30602, USA.
Curr Opin Immunol. 2009 Aug;21(4):385-90. doi: 10.1016/j.coi.2009.07.006. Epub 2009 Jul 29.
CD8(+) T cells have emerged as crucial players in the control of a number of protozoan pathogens, including Trypanosoma cruzi, the agent of human Chagas disease. The recent identification of the dominant targets of T. cruzi-specific T cells has allowed investigators to follow the generation of and document the functionality of T cell responses in both mice and humans. Although slow to develop in the early stages of the infection, T. cruzi-specific CD8(+) T cells reach prodigious levels and remain highly functional throughout chronic infections in mice. Following drug-induced cure during either the acute or chronic stage, these immunodominant T cells persist as stable, antigen-independent memory populations. T. cruzi-specific CD8(+) T cells in humans are less-well-studied but appear to lose functionality and decline in numbers in these decades-long infections. Changes in the frequency of parasite-specific T cell upon therapeutic treatment in humans may provide a new metric for determining treatment efficacy.
CD8(+) T细胞已成为控制多种原生动物病原体的关键参与者,包括人类恰加斯病的病原体克氏锥虫。最近对克氏锥虫特异性T细胞主要靶标的鉴定,使研究人员能够追踪小鼠和人类T细胞反应的产生并记录其功能。尽管在感染早期发展缓慢,但克氏锥虫特异性CD8(+) T细胞在小鼠慢性感染期间达到惊人水平,并始终保持高度功能。在急性或慢性阶段药物诱导治愈后,这些免疫优势T细胞作为稳定的、不依赖抗原的记忆群体持续存在。人类克氏锥虫特异性CD8(+) T细胞的研究较少,但在这些长达数十年的感染中似乎会失去功能且数量下降。人类接受治疗后寄生虫特异性T细胞频率的变化可能为确定治疗效果提供新的指标。